Starsource Multitrade

Starsource Multitrade CROIC

The Cash Return on Invested Capital (CROIC) of Starsource Multitrade (506365.BO) as of Oct 19, 2026 is -823.60 %. In the previous year, Cash Return on Invested Capital (CROIC) was -2.15 % — a change of 38,228.46% (lower).

CROIC

-823.60 %

YoY

38,228.46%

Last updated:

Cash Return on Invested Capital (CROIC) of Starsource Multitrade is 2026 -823.60 % . Cash Return on Invested Capital (CROIC) of Starsource Multitrade was 2025 -2.15 % . It decreases by 38,228.46% lower compared to the previous year.

The Starsource Multitrade CROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CROIC
Date
CROIC
Jan 1, 2019
-7.86 INR
Jan 1, 2020
44.97 INR
Jan 1, 2021
-3.71 INR
Jan 1, 2022
-2.84 INR
Jan 1, 2023
-5.89 INR
Jan 1, 2024
5.65 INR
Jan 1, 2025
-2.15 INR
Jan 1, 2026
-823.60 INR
The Starsource Multitrade CROIC history
YEARCROICYoY
-823.60 %+38,228.46%
-2.15 %-138.02%
5.65 %-195.95%
-5.89 %+107.16%
-2.84 %-23.43%
-3.71 %-108.26%
44.97 %-671.91%
-7.86 %-52.08%
-16.41 %-125.66%
63.96 %-212.32%
-56.94 %+5,610.72%
-1.00 %-70.79%
-3.41 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Starsource Multitrade Stock analysis

What does Starsource Multitrade do? Starsource Multitrade Ltd, identified by the ticker symbol 506365.BO and ISIN INE320M01019, is a corporate entity registered in India with its headquarters located in Mumbai, Maharashtra. The company was originally established through an initial public offering on January 2, 1995. While the specific sector and industry classifications are currently listed as not applicable, the company's operational history and strategic direction are closely tied to its former identity as Chemo Pharma Laboratories Ltd. This previous incarnation operated within the pharmaceutical industry, focusing on the development and distribution of healthcare products. However, the corporate landscape has shifted significantly, and the entity is no longer engaged in its original pharmaceutical activities. According to available information, the firm currently has no active operations within its traditional business lines. Instead, the organization is in a transitional phase, actively exploring new business opportunities to redefine its market presence. The strategic intent of the current management is to pivot away from pharmaceuticals and acquire businesses in the power and chemicals sectors. This move represents a substantial change in the company's core focus, aiming to diversify its portfolio and enter entirely different industrial segments. The company's official website, https://www.thechemopharmalaboratoriesltd.com/, reflects its historical branding, although the operational reality has evolved. Investors and stakeholders monitoring the company should note that the absence of current operations means that recent financial performance may not reflect traditional revenue streams associated with pharmaceutical manufacturing or sales. The focus is currently on strategic acquisitions and business development rather than organic growth from existing products. The transition from a pharmaceutical manufacturer to a holding or investment vehicle targeting power and chemical assets suggests a long-term restructuring plan. Until new acquisitions are finalized and integrated, the company remains in a state of exploration and preparation. The headquarters in Mumbai serves as the administrative center for these strategic discussions and future operational planning. The lack of a defined sector classification further underscores the company's current status as an entity in flux, waiting for new business units to be acquired and operationalized. This profile highlights the significant shift from its historical roots in healthcare to its current ambitions in energy and industrial chemicals, marking a distinct chapter in the company's corporate evolution. Starsource Multitrade is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Starsource Multitrade stock

Cash Return on Invested Capital (CROIC) of Starsource Multitrade is -823.60 % in 2026.

Cash Return on Invested Capital (CROIC) of Starsource Multitrade changed from -2.15 % to -823.60 %, representing a 38,228.46% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Return on Invested Capital (CROIC) Starsource Multitrade since 2006 – with annual values, charts, and detailed analysis.

CROIC measures the cash return generated on invested capital. Unlike ROIC, it uses free cash flow instead of accounting earnings, providing a purer profitability measure.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Return on Invested Capital (CROIC)'s Starsource Multitrade with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Return on Invested Capital (CROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Return on Invested Capital (CROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Starsource Multitrade

All Key Metrics — Starsource Multitrade